Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.00-0.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -108.91M | -63.31M | -79.45M | -97.94M | -134.84M |
| Total Depreciation and Amortization | 7.85M | 8.08M | 8.76M | 9.36M | 10.24M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.56M | 10.33M | 14.73M | 17.53M | 20.92M |
| Change in Net Operating Assets | 15.34M | 9.00M | 11.34M | 3.91M | -10.64M |
| Cash from Operations | -76.16M | -35.90M | -44.63M | -67.14M | -114.33M |
| Capital Expenditure | -240.00K | -291.00K | -267.00K | -267.00K | -2.79M |
| Sale of Property, Plant, and Equipment | 1.48M | 1.82M | 1.95M | 1.95M | 475.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 35.84M | 76.22M |
| Cash from Investing | 1.24M | 1.53M | 1.68M | 37.52M | 73.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 66.08M | 46.61M | 17.57M | 29.74M | 22.74M |
| Repurchase of Common Stock | -3.13M | -3.07M | -3.18M | -1.36M | -1.19M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 62.94M | 43.54M | 14.39M | 28.38M | 21.55M |
| Foreign Exchange rate Adjustments | 1.80M | 2.89M | -101.00K | -2.05M | 1.55M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.17M | 12.06M | -28.65M | -3.29M | -17.31M |